• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    1/21/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCUS alert in real time by email
    • Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies

     

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development organization and its late-stage portfolio, currently including four ongoing registrational Phase 3 studies, the first of which, STAR-221, is expected to read out next year. Arcus plans to initiate a fifth registrational Phase 3 study, PEAK-1, in the first half of 2025, to evaluate its HIF-2a inhibitor casdatifan plus cabozantinib in people with clear-cell renal cell carcinoma (ccRCC) who have progressed on immunotherapy. Dr. Markus's extensive late-stage development experience will be essential as he leads Arcus's strategy and efforts to fully leverage the opportunities in Arcus's portfolio.

    "Dr. Markus is a biotechnology industry veteran who will advance our late-stage programs into commercialization. His decades and breadth of clinical development success will solidify Arcus's emerging position as a leader in creating and developing a next generation of therapies in oncology," said Terry Rosen, Ph.D., chief executive officer of Arcus. "Our development organization has seamlessly advanced our broad portfolio of investigational molecules to address multiple cancers with high unmet need, and we are thrilled that Dr. Markus will be leading our organization and creating the infrastructure and culture to reproducibly deliver innovative therapies. I would also like to acknowledge and thank Dr. Nuyten for building a world-class development organization and leading Arcus through a period of incredibly rapid growth with parallel creation of a late-stage portfolio."

    "Arcus stands out as a mid-sized biotech company with its breadth and depth of oncology assets and entry into inflammation and immunology; it's an exciting time to be joining the company," said Richard Markus, M.D., Ph.D., incoming chief medical officer at Arcus Biosciences. "The company's portfolio of molecules, most of which are being developed on top of the current standards of care, has the potential to change clinical practice with meaningful advancements for patients. I'm looking forward to working with the oncology community and our clinical and business partners to make this a reality."

    Dr. Markus established a unique track record of late-stage development experience during a 13-year tenure at Amgen in increasing roles of responsibility, including as vice president of global development. Dr. Markus oversaw the development and approval of multiple products and was also the first R&D head for the biosimilars division, leading the development of a 10-product pipeline across multiple therapeutic areas, including oncology and rheumatology. Most recently, Dr. Markus founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company, where he served as president, CEO and member of the Board. Dr. Markus earned his medical degree and a Ph.D. in epidemiology from the University of Southern California, and then his surgery internship and residency in urology.

    Arcus's Ongoing and Announced Clinical Studies

    Trial Name

    Arms

    Setting

    Status

    NCT No.

    Upper Gastrointestinal Cancers

    STAR-221

    dom + zim + chemo vs. nivo + chemo

    1L Gastric, GEJ and EAC

    Ongoing Registrational Phase 3

    NCT05568095

    EDGE-Gastric (ARC-21)

    dom +/- zim +/- quemli +/- chemo

    1L/2L Upper GI Malignancies

    Ongoing

    Randomized Phase 2

    NCT05329766

    Lung Cancer

    STAR-121

     

    dom + zim + chemo vs. pembro + chemo

    1L NSCLC (PD-L1 all-comers)

    Ongoing Registrational Phase 3

    NCT05502237

    PACIFIC-8

     

    dom + durva vs. durva

    Unresectable Stage 3 NSCLC

    Ongoing Registrational Phase 3

    NCT05211895

    ARC-7

    zim vs. dom + zim vs. etruma + dom + zim

    1L NSCLC (PD-L1 ≥ 50%)

     

    Ongoing Randomized Phase 2

    NCT04262856

    ARC-10

    dom + zim vs. zim or chemo

    1L NSCLC (PD-L1 ≥ 50%)

     

    Ongoing Randomized Phase 2

    NCT04736173

    EDGE-Lung

    dom +/- zim +/- quemli +/- chemo

    1L/2L NSCLC (lung cancer platform study)

    Ongoing Randomized Phase 2

    NCT05676931

    VELOCITY-Lung

     

    dom +/- zim +/- etruma +/- sacituzumab govitecan-hziy or other combos

    1L/2L NSCLC (lung cancer platform study)

    Ongoing Randomized Phase 2

    NCT05633667

    Pancreatic Cancer

    PRISM-1

    quemli + gem/nab-pac vs. gem/nab-pac

    1L PDAC

    Ongoing Randomized Phase 3

    NCT06608927

    ARC-8

    quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac

    1L/2L PDAC

    Ongoing Randomized Phase 1/1b

    NCT04104672

    Kidney Cancer

    PEAK-1

    cas + cabo vs. cabo

    Post-IO ccRCC

    Planned Phase 3

    TBD

    ARC-20

    cas, cas + cabo

    Cancer Patients/ccRCC

    Ongoing Phase 1/1b

    NCT05536141

    Colorectal Cancer

    ARC-9

    etruma + zim + mFOLFOX vs. SOC

    2L/3L/3L+ CRC

    Ongoing

    Randomized Phase 2

    NCT04660812

    Head and Neck

    VELOCITY-HNSCC

    dom + zim + chemo vs zim + chemo

    1L

    Ongoing Phase 2

    NCT06727565

    Other

    ARC-25

    AB598

    Advanced Malignancies

    Ongoing

    NCT05891171

    ARC-27

    AB801

    Advanced Malignancies

    Ongoing

    NCT06120075

    cabo: cabozantinib; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; CRC: colorectal cancer; dom: domvanalimab; durva: durvalumab; EAC: esophageal adenocarcinoma; etruma: etrumadenant; GEJ: gastroesophageal junction; gem/nab-pac: gemcitabine/nab-paclitaxel; GI: gastrointestinal; HNSCC: head and neck squamous cell carcinoma; nivo: nivolumab; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; pembro: pembrolizumab; quemli: quemliclustat; SOC: standard of care; zim: zimberelimab

    About Arcus Biosciences

    Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences's clinical and preclinical programs, please visit www.arcusbio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Rosen's quote and statements regarding: expected timing for data readouts, including timing for a readout from STAR-221; the potency, efficacy or safety of Arcus's investigational products, including their potential to impact clinical practices or result in meaningful advancements for patients; and the initiation, design of and associated timing for future studies, including statements about PEAK-1. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks associated with preliminary and interim data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects in Arcus's investigational products; difficulties or delays in initiating or conducting clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; unfavorable global economic, political and trade conditions; Arcus's dependence on the collaboration with third parties such as Gilead and Taiho for the successful development and commercialization of its optioned molecules; difficulties associated with the management of the collaboration activities or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.

    The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250121029782/en/

    Investor Inquiries:

    Pia Eaves

    VP of Investor Relations & Strategy

    (617) 459-2006

    [email protected]

    Media Inquiries:

    Holli Kolkey

    VP of Corporate Affairs

    (650) 922-1269

    [email protected]

    Get the next $RCUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCUS

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    More analyst ratings

    $RCUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

      2/11/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

      Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

      1/21/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

      8/24/22 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Financials

    Live finance-specific insights

    See more
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

      New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

      4/23/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

      4/22/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Arcus Biosciences Inc.

      10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:12:08 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:09:59 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Arcus Biosciences Inc.

      DEFA14A - Arcus Biosciences, Inc. (0001724521) (Filer)

      4/22/25 4:11:06 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's common stock at an exercise price per share of $8.53, which was the closing price on May 8, 2025, and restricted stock units to acquire a total of 10,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      5/9/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and restricted stock units to acquire a total of 19,950 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      4/24/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arcus Biosciences upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

      2/26/25 7:16:55 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

      H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

      10/21/24 7:58:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Arcus Biosciences with a new price target

      Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

      10/8/24 7:34:04 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

      SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      12/17/24 9:52:58 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      11/12/24 9:50:12 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      10/17/24 11:31:06 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care